Viking Therapeutics enters the post-earnings stretch with its heaviest short position in months still intact — even as the stock slipped further following a wider-than-expected Q1 loss.
Short sellers have not blinked. At 20.1% of free float, the ORTEX short interest estimate is the dominant feature of Viking's positioning right now. The figure has actually eased modestly from its mid-March peak near 24%, trimming about 3.1% over the past week and roughly 5.8% over the past month. Yet 20% of float is still a formidable structural overhang for a clinical-stage biotech. The ORTEX short score of 75.9 — ranked in just the 6th percentile across the universe — underscores how heavily the shorts have leaned into this name. On the borrow side, conditions remain loose despite the elevated position size: cost to borrow has ticked up 26% on the week to 0.52%, but in absolute terms that is still close to zero. Availability is ample relative to the level of short interest, suggesting the lending market is not under pressure. That rules out any near-term mechanical squeeze from borrow scarcity alone.
Options traders are not loading up on either side. The put/call ratio of 0.21 is barely above its 20-day mean of 0.21 — a z-score of just 0.33 — and sits near the 52-week low of 0.19. Far from the defensive hedging one might expect after a miss, the options market remains dominated by call volume. That is a nuanced signal: it suggests the investor base is still leaning bullish directionally, even as the stock has dropped 8.5% over the week to close at $31.33.
The Street is still broadly constructive, but targets have started to slip. The most recent move came today from Cantor Fitzgerald, which trimmed its price target on Viking from $105 to $100 while keeping an Overweight rating — a trim rather than a retreat. Morgan Stanley also cut its target to $95. With the consensus mean around $92.50, both targets remain well above the current price, implying substantial upside at face value. However, the gap between the $31 stock and $90-plus targets reflects that the market is applying a heavy clinical-risk discount — and the Q1 EPS miss of $1.37 against an estimate of $1.02 widens that lens. Viking is pre-revenue, burning cash at an operating level of around $453 million annually, and the valuation debate is almost entirely a function of pipeline newsflow. The company's enterprise value of roughly $3.4 billion reflects a pipeline optionality bet, not current earnings.
The pipeline narrative does give bulls something concrete to hold onto. Viking confirmed it plans to start Phase III trials for oral VK2735 in Q4 2026, with a 52-week VANQUISH extension study also in motion. The bull case centres on Viking's position as one of the few independent, late-stage obesity and metabolic therapeutics players — a narrowing field where strong data can command premium valuations and partnership interest. Bears point to the binary nature of clinical readouts, regulatory risk, and the pressure on biotech licensing deals, particularly involving US-China dynamics. EPS surprise ranks in the 84th percentile historically, but Q1's miss cuts against that pattern.
Institutionally, the ownership base is stable. Vanguard holds 8.6% and added modestly in Q1. BlackRock and Fidelity (FMR) each added over one million shares in the quarter. The consistent building by passive and active large managers provides a demand floor even as the shorts maintain their position. The next scheduled event is a May 19 earnings call, which the Q3 maintenance study data — flagged as a potential wildcard by analysts — may make more consequential than usual.
The tension between a structurally large short position, a still-bullish options skew, and a stock trading at a 65% discount to the analyst mean target means the May 19 catalyst deserves close attention: what the VANQUISH extension data shows, and whether Viking refines its Q4 Phase III timeline, will determine whether the shorts begin to cover in earnest or press their advantage.
See the live data behind this article on ORTEX.
Open VKTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
